Signal2026-07-23
ClinicalTrials.gov

[PHASE2] Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

Part of

Emerging Clinical Immunotherapy And Treatment Trials

Open primary sourceSee the whole picture